

STEM CELLS

Airway stem cells sense hypoxia and differentiate into protective solitary neuroendocrine cells

Manjunatha Shivaraju^{1,2,3}, Udbhav K. Chitta⁴, Robert M. H. Grange⁵, Isha H. Jain^{6,7,8*}, Diane Capen⁹, Lan Liao¹⁰, Jianming Xu¹⁰, Fumito Ichinose⁵, Warren M. Zapol⁵, Vamsi K. Mootha^{6,7,8}, Jayaraj Rajagopal^{1,2,3,†}

Neuroendocrine (NE) cells are epithelial cells that possess many of the characteristics of neurons, including the presence of secretory vesicles and the ability to sense environmental stimuli. The normal physiologic functions of solitary airway NE cells remain a mystery. We show that mouse and human airway basal stem cells sense hypoxia. Hypoxia triggers the direct differentiation of these stem cells into solitary NE cells. Ablation of these solitary NE cells during hypoxia results in increased epithelial injury, whereas the administration of the NE cell peptide CGRP rescues this excess damage. Thus, we identify stem cells that directly sense hypoxia and respond by differentiating into solitary NE cells that secrete a protective peptide that mitigates hypoxic injury.

Airway neuroendocrine (NE) cells were first identified as epithelial cells that store and secrete amines and peptides from membrane-bound vesicles, mirroring the process of neurotransmitter release from neurons. Indeed, both neurons and airway NE cells secrete serotonin and calcitonin gene-related peptide (CGRP) (1, 2). NE cell hyperplasia occurs in diverse lung diseases, including neuroendocrine hyperplasia of infancy (NEHI), sudden infant death syndrome (SIDS), asthma, congenital pneumonia, pulmonary hypertension, cystic fibrosis, congenital diaphragmatic hernia, and chronic obstructive pulmonary disease (COPD) (3, 4). However, both the cause and relevance of NE cell hyperplasia remain unknown.

NE cells can be found as solitary cells or clustered as neuroepithelial bodies (NEBs). In mice, solitary pulmonary NE cells are found in the trachea and primary bronchi, but in humans, they are scattered throughout the airway tree. By contrast, the neuroepithelial bodies (NEBs) of mice are clustered groups of NE cells found specifically at airway branch points, whereas their presumed human NEB counterparts are less stereotypically distrib-

uted throughout the airway epithelium (5, 6). NEBs are reported to perform various physiologic functions, including oxygen sensing (7), mechanotransduction (8, 9), modulating pulmonary blood flow (9), chemosensation (9), and regulating inflammation (10). Additionally, murine NEBs are thought to serve as niches for adjacent progenitor cells (11). However, the physiologic functions of solitary NE cells are largely unknown. One study of human solitary NE cells in vitro suggests that they function as airway chemosensory cells in vivo (12). Human solitary NE cells secrete CGRP in culture, and it is hypothesized that this neuropeptide links epithelial stimulus detection to the modulation of stem cell behavior (12).

Murine NEBs contain a subpopulation of NE stem cells that rarely produce new NE cells under steady-state conditions. However, following injury, NE stem cells generate more NE cells, leading to larger NEBs. The NE stem cells of NEBs are also plastic and contribute to the lineage of non-NE epithelial cells in their immediate vicinity (13). Despite this plasticity, genetic ablation of NEBs fails to elicit a gross effect on airway epithelial regeneration (14). By contrast, solitary NE cells display rapid turnover and are regularly replaced by basal stem cells (15, 16). The divergent lineage and kinetics of solitary NE cells and NEB-localized NE cells suggests that their functions may be distinct.

After birth, as the airway epithelium is first exposed to ambient oxygen, NE cell numbers decline (17–19). Hypoxia is known to delay the normal postnatal disappearance of NE cells in rabbit airway epithelia, but the mechanism is not understood (17). Elimination of oxygen-sensing prolyl hydroxylases (PHDs) from NEB-resident NE cells results in NEB growth (20). Because solitary NE cells are derived from basal stem cells rather than preexisting NE cells, we postulated that basal stem cells might possess an oxygen-sensing

mechanism that triggers hypoxia-stimulated stem cells to undergo solitary NE cell differentiation. We further speculated that these hypoxia-induced solitary NE cells would have a protective physiologic function in the setting of hypoxia. The coincident occurrence of solitary NE cells and basal cells is characteristic of the majority of the human airway tree, so we used the murine trachea as a model system to study solitary NE cell biology because it is the only part of the murine respiratory tree that contains both solitary NE cells and basal stem cells (21).

Hypoxia induces solitary NE cell differentiation

When mice were exposed to hypoxic conditions (F₂O₂ 8%) (fig. S1), we observed a significant time-dependent increase in solitary NE cells (Fig. 1, A and B). To exclude the possibility of injury-induced nonspecific expression of NE cell markers by non-NE cells, we assessed the expression of the NE cell fate-determining transcription factor *Ascl1*. *Ascl1-CreERT2::Rosa26-tdTomato* (hereafter referred to as *Ascl1-tdTomato*) mice were exposed to 20 days of hypoxia (fig. S2A), and tamoxifen was administered to label *Ascl1*⁺ NE cells. We observed a significant increase in *Ascl1-tdTomato*⁺ cells (fig. S2, B and C), confirming NE cell differentiation. Finally, quantifying the fraction of cells possessing NE cell-specific vesicles by electron microscopy confirmed the potent induction of bona fide solitary NE cells (Fig. 1, C and D).

We next sought to determine the cellular origin of the hypoxia-induced solitary NE cells. Because the deletion of PHDs, which mimics hypoxia, results in NEB growth (20), we assessed whether hypoxia could similarly cause solitary NE cells to self-renew. Preexisting solitary NE cells in *Ascl1-tdTomato* mice were lineage labeled, and then animals were subjected to hypoxia. The incorporation of 5-bromodeoxyuridine (BrdU) over the entire period of hypoxia was measured as an index of replication (fig. S3A). Although solitary NE cell numbers increased significantly after hypoxia (fig. S3, B and C), we did not observe any lineage-labeled cells or chromogranin A–positive (CHGA⁺) solitary NE cells positive for Ki67 (fig. S3, B and D), and very few arose from NE cell replication (4.41% of lineage-labeled NE cells were BrdU⁺) (fig. S3, E and F). Thus, NE cell replication does not account for the accumulation of solitary NE cells.

Basal stem cells are the source of hypoxia-induced solitary NE cells

To assess whether basal stem cells are the source of hypoxia-induced solitary NE cells, we lineage labeled basal stem cells using *p63-CreER::R26R-tdTomato* mice (hereafter referred to as *p63-tdTomato*, 97% labeling efficiency) and

¹Center for Regenerative Medicine, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA.

²Departments of Internal Medicine and Pediatrics, Pulmonary and Critical Care Division, Massachusetts General Hospital, Boston, MA 02114, USA. ³Harvard Stem Cell Institute, Cambridge, MA 02138, USA. ⁴Northeastern University, 360 Huntington Ave., Boston, MA 02115, USA. ⁵Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. ⁶Department of Molecular Biology and Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, MA, USA.

⁷Department of Systems Biology, Harvard Medical School, Boston, MA, USA. ⁸Broad Institute of Harvard and MIT, Cambridge, MA, USA. ⁹Program in Membrane Biology and Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ¹⁰Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.

*Present address: Department of Physiology, University of California San Francisco, San Francisco, CA 94158, USA.

†Corresponding author. Email: jrajagopal@partners.org




Fig. 1. Hypoxia leads to an increase in solitary neuroendocrine (NE) cell numbers in the adult mouse trachea. (A) Immunostaining for NE cell markers PGP9.5 (yellow) and CHGA (magenta). (B) Quantification of the percentage of CHGA⁺, PGP9.5⁺ and double-positive solitary NE cells in tracheal sections ($n = 8$). Dotted lines indicate basement membrane and cell borders. (C) Transmission electron microscopy (TEM) images of solitary NE cells and (D) quantification of

cells with NE vesicles after 25 days of normoxia and hypoxia ($n = 2$) (total 300 nuclei from each condition). Blue arrows indicate empty core vesicles, and red arrows point to empty degranulating vesicles. Dotted magenta lines demarcate NE cell borders. $n =$ biological replicates/condition repeated three times (three independent experiments excluding TEM experiments). *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$; error bars, means \pm SD. Scale bars, 20 μ m (unless indicated otherwise).

subjected the mice to hypoxia (fig. S4). This revealed that the basal stem cells are indeed the source of hypoxia-induced solitary NE cells (Fig. 2A). Furthermore, electron microscopy revealed the presence of basal stem cells that expressed abundant vesicles. After hypoxia, $4 \pm 0.49\%$ of basal cells exhibited NE-specific vesicles (Fig. 2B), which were normally absent. These data point to a direct differentiation of basal cells into solitary NE cells.

Although basal cells clearly contribute to the pool of hypoxia-induced solitary NE cells, a significant increase in the number of unlabeled CHGA⁺ tdTomato⁺ cells after basal cell lineage tracing was observed, implying contributions from other cells (Fig. 2A). Because airway secretory cells have been shown to be plastic (22), we lineage labeled secretory cells using *Scgbl1a1-CreERT2::Rosa26-tdTomato* mice (labeling efficiency $62 \pm 5.02\%$) and then subjected the mice to hypoxia (fig. S5A). A small increase in the fraction of lineage-labeled CHGA⁺ solitary NE cells occurred (fig. S5B), revealing that secretory cells can undergo limited NE cell differentiation. Of the non-neuroendocrine cells contributing to the pool of hypoxia-induced solitary NE cells, basal cells are the major contributors (76%), followed by secretory cells (4 to 8%) (fig. S5C).

Basal stem cells sense hypoxia

We next sought to determine the molecular basis of NE cell differentiation. Oxygen-requiring PHDs act as molecular oxygen sensors (23). During normoxia, PHDs hydroxylate hypoxia-inducible factor alpha (HIF α), which in turn leads to HIF α ubiquitination and degradation. This fails to occur during hypoxia, and stabilized HIF α activates numerous genes associated with the hypoxia response. To address whether PHDs play a similar role in the airway epithelium, we used small molecules that stabilize HIFs in a hypoxia-mimetic state, including the PHD inhibitor FG-4592 and a HIF- α -pVHL interaction inhibitor, CoCl₂ (24, 25). Both inhibitors stabilized HIF-1 α and HIF-2 α in cultured epithelium (fig. S6, A to C). *Ascl1-tdTomato* mice were treated with varying doses of FG-4592 over 20 days, and then tamoxifen was administered to label *Ascl1*⁺ solitary NE cells (fig. S7A). A significant dose-dependent increase in tdTomato⁺ cells occurred (fig. S7, B and C). Analogous results were obtained with an independent NE cell lineage driver, *Cgrip-CreERT2::Rosa26-tdTomato* (hereafter *Cgrip-tdTomato*) (fig. S7, D and E). A significant increase in solitary NE cells was also observed after CoCl₂ administration (fig. S7, F to H).

To assess whether molecular oxygen sensing specifically occurs within the stem cell compartment per se, we genetically activated HIF signaling in vivo by conditionally deleting all three PHDs exclusively in basal stem cells using mice harboring *p63-CreERT2* and *Rosa26-tdTomato::Phd1^{fl/fl}::Phd2^{fl/fl}::Phd3^{fl/fl}* alleles (hereafter referred as *p63-Phds*) (fig. S8). This stabilized HIF-1 α and HIF-2 α in a two-dimensional culture system (fig. S9, A to C). After tamoxifen-induced deletion, CHGA⁺ NE cell numbers increased (Fig. 3A). This demonstrates that stem cells harbor a molecular oxygen-sensing mechanism and that stem cell-specific HIF activation triggers those same stem cells to directly differentiate into NE cells.

To identify the specific HIF isoform involved in solitary NE cell differentiation, we specifically activated either *Hif1a* or *Hif2a* by conditionally deleting one *Hif* at a time in basal stem cells (*p63-CreERT2::Rosa26-tdTomato::Hif1a^{fl/fl}* or *Hif2a^{fl/fl}*) and stabilizing the other through FG-4592 administration (fig. S10). Enforced HIF1 α stabilization and *Hif2a* deletion augmented FG-4592-induced CHGA⁺ NE cell induction, whereas HIF2 α -stabilization and *Hif1a* deletion completely blocked it (Fig. 3B). Thus, the stem cell NE




Fig. 2. Hypoxia leads to increased solitary NE cell numbers by accelerating the differentiation of basal stem cells into NE cells. (A) Immunostaining for CHGA (green) and p63 (white) and quantification of the absolute number of indicated cells from *p63-tdTomato* lineage-labeled mice exposed to hypoxia. (B) Transmission electron microscopy images of tracheal sections after 25 days of normoxia or hypoxia. After hypoxia, cells with characteristic features of basal cells contain apically located secretory vesicles. Basal cells with and without secretory vesicles are quantified (200 nuclei from each condition). Dotted black lines indicate basement membrane, magenta lines demarcate cell boundaries. Blue arrows point to empty core vesicles, and red arrows point to empty degranulated vesicles. n.s., not significant; *** $p < 0.001$, * $p < 0.05$; error bars, means \pm SD. Scale bars, 20 μ m (unless indicated otherwise).

differentiation program is *Hif1a* dependent, and *Hif2a* is a negative regulator of this process.

Hypoxia-induced solitary NE cells mediate a protective tissue response

The epithelial damage induced by hypoxia is characterized by epithelial cell apoptosis and a compensatory stem cell hyperplasia (Fig. 4, A and B, columns 1 and 3, and Fig. 5, A and B). We hypothesized that hypoxia-induced solitary NE cells could mediate a protective tissue response in this setting. To assess the functional consequences of solitary NE cell loss, we used compound mice carrying the NE cell-specific *CGRP-CreER* driver allele and a floxed DTA allele. Intranasal administration of a low dose of 4-hydroxytamoxifen was used to achieve airway-specific NE cell ablation, as evidenced by a reduction in CHGA staining (efficiency $\sim 88 \pm$

2%) (Fig. 5C). NE cell ablation during normoxia did not significantly alter epithelial apoptosis or cell proliferation (Fig. 4B, columns 1 and 2, and Fig. 5, A and B), whereas in the setting of hypoxia, it resulted in a marked increase in apoptosis (Fig. 4B columns 3 and 4, and Fig. 5A) and a drop in epithelial cell proliferation (Fig. 4B, column 3 and 4, and Fig. 5B). Ciliated cells were most prone to apoptosis, whereas basal stem cells were the most hypoxia resistant (fig. S11, A and B). Basal cells were also the dominant cell population undergoing hypoxia-induced proliferation, although secretory cells also divided (fig. S12, A and B). NE cell ablation has no effect during normoxia, but in the setting of hypoxia, the loss of NE cells results in a significant decrease in basal stem cell and secretory cell progenitor cell proliferation (fig. S12, A and B).

Next, we tried to identify an NE cell-associated factor that promotes stem and progenitor cell hyperplasia and/or prevents apoptosis in the setting of hypoxia. We noted that CGRP levels increase after hypoxia (26) and that CGRP serves as a mitogen in rat lung alveolar epithelial cells (27) and murine sub-mucosal gland progenitor cells (28). We then confirmed that epithelial CGRP expression in the trachea is found exclusively in *Ascl1*-positive solitary NE cells (fig. S13, A and B). At baseline, 54% of *Ascl1*-positive NE cells are CGRP immunoreactive, which sharply increases to 92% after hypoxia (fig. S13C). Nasal administration of CGRP to normoxic wild-type mice resulted in increased epithelial cell proliferation (fig. S13D). Costaining with cell type-specific markers and Ki67 identified replicating basal stem cells ($CK5^+Ki67^+$) and a smaller increase in replicating secretory cells ($SCGB1A1^+Ki67^+$) (fig. S13, D to F). Furthermore, we were able to block CGRP-stimulated proliferation using the CGRP-receptor inhibitor BIBN-4096 (29) (fig. S13, D to F).

Next, we intranasally administered CGRP peptide after NE cell ablation to assess whether the presence of CGRP could compensate for the loss of whole NE cells. CGRP restored epithelial proliferation to amounts normally observed after hypoxia and also prevented epithelial apoptosis (Fig. 4B, columns 3 to 5, and Fig. 5, A and B). Furthermore, proliferation was restored in both basal stem cells and secretory cells (fig. S14, A and B). Ciliated cells were the predominant cell type protected from apoptosis, although basal stem cells were also protected (fig. S11B). The CGRP-receptor inhibitor BIBN-4096 appropriately blocked the CGRP-mediated effects on cell type-specific apoptosis and proliferation (Fig. 4B, columns 5 and 6, and figs. S11A, columns 5 and 6, and S14). TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) staining confirmed these findings (fig. S15, A and B).

To determine whether CGRP sourced from cells other than solitary NE cells contributes to epithelial protection, we assessed which other cell types were ablated in our *Cgrp-CreERT2::Rosa26-DTA* model. We noted that tracheal innervation was lost, so we used an *Ascl1-CreERT2::Rosa26-DTA* model to eliminate solitary NE cells and spare CGRP-expressing neuronal populations (fig. S16). The results closely mirrored our findings with the *Cgrp-CreERT2::Rosa26-DTA* model (fig. S17). Additionally, the administration of CGRP inhibitor to hypoxic animals with intact solitary NE cells resulted in a significant increase in apoptosis and a drop in proliferation, consistent with a protective role for CGRP (fig. S17, B, C, columns 5 and 7, D, and E). Moreover, hypoxia led to increased epithelial expression of the CGRP receptors RAPM1 and CALCRL (fig. S18, A and B), suggesting increased CGRP signal reception.




Fig. 3. Stem cells sense hypoxia using prolyl hydroxylases and then differentiate into solitary NE cells. (A) Immunostaining for CHGA (yellow) and quantification of NE cells after deletion using *p63-CreER::PhDs* mice. **(B)** Immunostaining for CHGA (yellow) and quantification of CHGA⁺ cells from

p63-Hif1α or *p63-Hif2α* mice treated with FG-4592 ($n = 5$). In the merged image, the overlap of yellow (CHGA), blue (DAPI, 4',6-diamidino-2-phenylindole), and tdTomato appears white. **** $p < 0.0001$, *** $p < 0.001$; error bars, means \pm standard deviation. Scale bars, 20 μ m.

We next sought to assess whether CGRP secreted by NEBs was acting as a long-range protective factor, originating in the intrapulmonary airway epithelium where NEBs occur, and acting directly or indirectly on the remote tracheal epithelium. Using *Ascl1-tdTomato* mice to lineage label preexisting NEBs, we confirmed that hypoxia triggers NEB hyperplasia, consistent with the previously reported finding that NEBs lacking PHDs become larger (20). Although there was no significant increase in the total number of NEBs (fig. S19, A to D), scattered NEBs did contain rare Ki67 cells (4 to 10 NEBs per left lobe of the lung) (fig. S19C). However, despite the efficient ablation of tracheal solitary NE cells in our model system, NEBs were unaffected (fig. S20). This suggests that solitary NE cells are the source of protective CGRP in our model system and that this peptide acts locally to protect adjacent epithelial cells from hypoxia-induced damage. However, these findings do not exclude a physiologic role for pools of CGRP produced elsewhere.

Finally, we assessed the effects of hypoxia on human airway epithelia grown from airway basal stem cells. Stabilizing HIFs by adding FG-4592 significantly increased the number of solitary NE cells (fig. S21). This system should prove useful in defining the role of solitary NE cells in diseases characterized by NE cell excess, paralleling the use of such models

in dissecting the root mechanisms of cystic fibrosis.

Discussion

We have shown that hypoxia-induced murine solitary NE cells are necessary for repairing hypoxia-induced epithelial damage. The mechanism invokes the secretion of a protective paracrine signal. We speculate that the diffuse distribution of solitary NE cells throughout the human airway, in contrast to the discrete location of murine NEBs at airway bifurcations, forms the basis of a distributed tissue-wide protection system in which effective epithelial repair can be fostered throughout the length of the airway tree.

Oxygen therapy is used in the setting of respiratory failure in many diseases associated with NE cell excess, ranging from severe asthma to cystic fibrosis to COPD, but oxygen has also been associated with multiple forms of toxicity (30). If hypoxia-induced solitary NE cells are indeed protective in disease states, supportive oxygen therapy might result in unintended consequences by reducing the physiologic stimulus for generating protective NE cells. By contrast, in neuroendocrine hyperplasia of infancy (NEHI), where NE cell excess appears to be a primary pathology, supplemental oxygen might act as a primary therapy by triggering a reduction in pathologic NE cell numbers. Indeed, some

patients with NEHI have a sudden improvement with oxygen administration that is uncharacteristic of related respiratory disorders of childhood, which display a slow and graded response to oxygen therapy (31).

With regards to normal physiology, our findings may help explain why NE cell numbers decrease after birth (17–19, 32) because oxygen levels increase after air breathing, as well as why high altitude is associated with increased numbers of NE cells (33). It may also explain why Notch loss-of-function experiments produce increased numbers of NE cells in the embryonic epithelium, whereas they do not in the air-breathing adult. Finally, it is of interest to note that sudden infant death syndrome (SIDS) has been associated with hypoxia, NE cell excess, and elevated serotonin levels (34, 35).

In this study, we have identified a conserved tissue-level response to a fundamental form of stress, oxygen deprivation. In this instance, sentinel stem cells detect hypoxia and produce a specific protective cell type that is needed to mitigate the effects of the hypoxia. Although we have identified CGRP as a protective airway solitary NE cell factor, NE cells can secrete a host of other neuropeptides and amines. Thus, we speculate that different forms of pulmonary injury might engender varied protective NE cell responses. It will be of great interest to assess whether other organ-specific stem cells




Fig. 4. Solitary NE cells are required for the repair of hypoxia-induced injury. (A) Schematic representation of the protocol for assessing the functional consequences of NE cell ablation in the setting of hypoxia-induced injury. (B) Immunostaining for CHGA (green), Cleaved caspase-3 (magenta) and Ki67 (white) on normoxic and hypoxic tracheal epithelium with and without NE cell ablation and in combination with CGRP rescue and CGRP receptor inhibitor administration. (*n* = 5). ****p* < 0.001, ***p* < 0.01, **p* < 0.05; error bars, means ± standard deviation. Scale bars 30 μm.




Fig. 5. CGRP stimulates progenitor replication and prevents epithelial apoptosis. Quantification of (A) Cleaved caspase-3⁺ cells, (B) Ki67⁺, and (C) CHGA⁺ cells under normoxic or hypoxic conditions with and without NE cell ablation coupled to CGRP administration or blockade. Tissue samples from Fig. 4. ****p* < 0.001; error bars, means ± SD.

more generally execute their own specific protective behaviors when triggered by hypoxia. It will also be important to determine whether the stem cells of other organs respond to local hypoxia by generating their own distinctive populations of protective NE cells.

REFERENCES AND NOTES

1. F. Feyrter, *Virchows Arch. Pathol. Anat. Physiol.* **320**, 551–563 (1951).
2. F. Feyrter, *Virchows Arch. Pathol. Anat. Physiol. Med.* **325**, 723–732 (1954).
3. E. Cutz, *Semin. Diagn. Pathol.* **32**, 420–437 (2015).
4. E. Cutz, H. Yeger, J. Pan, T. Ito, *Curr. Respir. Med. Rev.* **4**, 174–186 (2008).
5. M. Noguchi, K. Sumiyama, M. Morimoto, *Cell Rep.* **13**, 2679–2686 (2015).
6. C. S. Kuo, M. A. Krasnow, *Cell* **163**, 394–405 (2015).
7. E. Cutz, A. Jackson, *Respir. Physiol.* **115**, 201–214 (1999).
8. R. I. Linnoila, *Lab. Invest.* **86**, 425–444 (2006).
9. E. Cutz, J. Pan, H. Yeger, N. J. Domnik, J. T. Fisher, *Semin. Cell Dev. Biol.* **24**, 40–50 (2013).
10. K. Branchfield et al., *Science* **351**, 707–710 (2016).
11. S. D. Reynolds et al., *Am. J. Physiol. Lung Cell. Mol. Physiol.* **278**, L1256–L1263 (2000).
12. X. Gu et al., *Am. J. Respir. Cell Mol. Biol.* **50**, 637–646 (2014).
13. Y. Ouadah et al., *Cell* **179**, 403–416.e23 (2019).
14. H. Song et al., *Proc. Natl. Acad. Sci. U.S.A.* **109**, 17531–17536 (2012).
15. D. T. Montoro et al., *Nature* **560**, 319–324 (2018).
16. J. K. Watson et al., *Cell Rep.* **12**, 90–101 (2015).
17. I. M. Keith, J. A. Will, *Thorax* **36**, 767–773 (1981).
18. N. S. Track, E. Cutz, *Life Sci.* **30**, 1553–1556 (1982).
19. H. Moosavi, P. Smith, D. Heath, *Thorax* **28**, 729–741 (1973).
20. J. Pan, T. Bishop, P. J. Ratcliffe, H. Yeger, E. Cutz, *Hypoxia (Auckl.)* **4**, 69–80 (2016).
21. J. R. Rock, S. H. Randell, B. L. M. Hogan, *Dis. Model. Mech.* **3**, 545–556 (2010).
22. P. R. Tata et al., *Nature* **503**, 218–223 (2013).
23. C. Willam, L. G. Nicholls, P. J. Ratcliffe, C. W. Pugh, P. H. Maxwell, *Adv. Enzyme Regul.* **44**, 75–92 (2004).
24. K. Wu et al., *Brain Res.* **1632**, 19–26 (2016).
25. Z.-J. Dai et al., *J. Exp. Clin. Cancer Res.* **31**, 28 (2012).
26. D. R. Springall et al., *J. Pathol.* **155**, 259–267 (1988).
27. Y. Kawanami et al., *Respir. Res.* **10**, 8 (2009).
28. W. Xie et al., *J. Clin. Invest.* **121**, 3144–3158 (2011).
29. H. Doods et al., *Br. J. Pharmacol.* **129**, 420–423 (2000).
30. P. Tinitis, *Ann. Emerg. Med.* **12**, 321–328 (1983).
31. S. Caimmi et al., *Ital. J. Pediatr.* **42**, 84 (2016).
32. E. R. Spindel et al., *J. Clin. Invest.* **80**, 1172–1179 (1987).
33. J. R. Gosney, *Anat. Rec.* **236**, 105–107, discussion 108–112 (1993).
34. K. Aita et al., *Leg. Med.* **2**, 134–142 (2000).
35. P. M. A. Siren, *Ups. J. Med. Sci.* **121**, 199–201 (2016).

ACKNOWLEDGMENTS

We thank the members of the Rajagopal lab and R. Chivukula for constructive criticism. We thank P. Chuang for providing *Cgrp-CreER*. We thank New England Donor Services (NEDS) for providing human airway samples. Finally, we thank E. Cutz for his constructive criticism and for reminding us of the history of NE cell biology. **Funding:** J.R. is supported by the New York Stem Cell Foundation, the National Institutes of Health–National Heart, Lung, and Blood Institute (R01HL118185, and 1R01HL148351-01A1), and the Ludwig Cancer Institute at Harvard. J.X. is supported by R01CA193455. Electron microscopy was performed in the Microscopy Core of the MGH Program in Membrane Biology, which

is partially supported by an Inflammatory Bowel Disease Grant (DK043351) and a Boston Area Diabetes and Endocrinology Research Center (BADERC) Award (DK057521). **Author contributions:** M.S. conceived, designed, and performed the experiments and co-wrote the manuscript; U.K.C. performed immunostaining and counting cell numbers; R.M.H.G., I.H.J., and F.I. provided guidance on the use of hypoxia chambers; D.C. performed electron microscopy imaging; L.L. and J.X. provided *p63-CreER* mice; W.M.Z. and V.K.M. provided guidance on hypoxia experiments; and J.R. supervised the work and co-wrote the manuscript. All authors reviewed and edited the manuscript for accuracy. **Competing interests:** V.K.M. is a paid adviser to Janssen Pharmaceuticals and Sam Ventures and is a founder of and owns equity in Raze Therapeutics. V.K.M., I.H.J., and W.M.Z. are listed as inventors on patent application (WO2017027810A2) submitted by Massachusetts General Hospital on therapeutic uses of hypoxia for mitochondrial disease. **Data and materials availability:** *p63-CreER* mice are available from J. Xu under a materials transfer agreement with the Baylor College of Medicine. All data are available in the manuscript or the supplementary materials.

SUPPLEMENTARY MATERIALS

science.sciencemag.org/content/371/6524/52/suppl/DC1
Materials and Methods
Figs. S1 to S21
References (36–40)
MDAR Reproducibility Checklist

[View/request a protocol for this paper from Bio-protocol.](#)

31 October 2019; accepted 29 October 2020
10.1126/science.aba0629

Airway stem cells sense hypoxia and differentiate into protective solitary neuroendocrine cells

Manjunatha Shivaraju, Udbhav K. Chitta, Robert M. H. Grange, Isha H. Jain, Diane Capen, Lan Liao, Jianming Xu, Fumito Ichinose, Warren M. Zapol, Vamsi K. Mootha and Jayaraj Rajagopal

Science **371** (6524), 52-57.
DOI: 10.1126/science.aba0629

Protecting the lung from hypoxic stress

The lung experiences constantly changing oxygen concentrations and must recognize and respond to a low-oxygen environment. Shivaraju *et al.* reveal that airway stem cells directly sense hypoxia and respond by differentiating into protective neuroendocrine (NE) cells that secrete a peptide that mitigates tissue damage (see the Perspective by Zacharias). This work suggests that the observed NE cell hyperplasia that accompanies lung diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease represents a compensatory physiologic response. More broadly, it raises the possibility that stem cells throughout the body sense hypoxia and differentiate into organ-specific NE cells.

Science, this issue p. 52; see also p. 32

ARTICLE TOOLS

<http://science.sciencemag.org/content/371/6524/52>

SUPPLEMENTARY MATERIALS

<http://science.sciencemag.org/content/suppl/2020/12/29/371.6524.52.DC1>

RELATED CONTENT

<http://science.sciencemag.org/content/sci/371/6524/32.full>

REFERENCES

This article cites 40 articles, 7 of which you can access for free
<http://science.sciencemag.org/content/371/6524/52#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science* is a registered trademark of AAAS.

Copyright © 2021, American Association for the Advancement of Science